Treatment with the anti-CD38 antibody in mice that are resistant to IC blockade therapy inhibits tumor growth, enhances effector CD8+ and CD4+ T-cell responses and reduces CD4+ Treg cells and MDSCs [46]. The gene discussed is CD8A; the disease is neoplasm.